For people with atrial fibrillation (Afib), investigational abelacimab proved to be a potent dual factor XI/XIa inhibitor with much lower safety risks compared with a direct oral anticoagulant (DOAC), ...
Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...
Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients ...
Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to ...
The Healthy on MSN5mon
6 Silent Signs of AFib, According to a CardiologistAn irregular heartbeat can raise your risk for heart failure and stroke. With up to 6 million Americans estimated to have ...
Boston Scientific Corp. reported positive data for two key atrial fibrillation therapies at AF Symposium 2025 on January 17.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback